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1. Introduction 
Pyrrolidone carboxylic acid (PCA) has been known 
as a cyclic derivative of glutamic acid for more than 
90 years [ 11. An enzyme designated y-glutamyl cyclo- 
transferase (y-glutamyl lactamase) was found in mam- 
malian tissues [2] that catalyzes the conversion of L- 
y-glutamyl amino acids to L-PCA and free amino acids. 
This reaction represents probably the main route of 
formation of L-PCA in mammals [3,4]. L-PCA was 
found at the N-terminus of a number of peptides and 
proteins (for a review see [5]), and this compound 
was also postulated to be an intermediate of the y-glu- 
tamyl cycle, which was proposed as a transport system 
for amino acids [6]. Although these considerations in- 
dicate that L-PCA is an active metabolite, there are no 
reports demonstrating its presence as a normal constit- 
uent of body fluids and tissues. Indeed screening meth- 
ods in which gas chromatographic procedures were 
used for the determination of PCA as the methyl ester, 
failed to detect this compound in normal body fluids 
171. 
We report the finding of siginificant amounts of 
PCA in tissues and body fluids by the application of a 
gas liquid chromatographic procedure, utilizing elec- 
tron capture detection. Analysis of the optical config- 
uration of glutamate derived by acid hydrolysis from 
PCA has shown that all of the PCA present in the 
cerebrospinal fluid is of the L-configuration and that 
a substantial fraction of the PCA in urine has the D- 
configuration. 
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2. Materials and methods 
All coated gas chromatographic packings were ob- 
tained from Applied Science Labs, State College, Penn- 
sylvania. Pentafluoropropanol was purchased from 
PCR chemicals, Gainesville, Florida, and pentafluoro- 
propionic anhydride from Pierce Chemical Company, 
Rockford, Illinois. 
[14 C]L-PCA was prepared by cyclization of [ l4 C]L- 
glutamate as previously described [8]. L-Glutamic acid 
decarboxylase purified from E. coli was obtained from 
Sigma Chemical Company. Gas chromatography was 
performed on a Packard 7400 series gas chromatograph 
fitted with a 150 mCi tritium electron capture detector. 
Freshly voided urine and fresh serum samples were ob- 
tained from healthy normal human subjects. Fresh 
samples of spinal fluid were obtained by lumbar punc- 
ture from neurologic and psychiatric patients and pa- 
tients with herniated discs. 
Tissue extracts were prepared by homogenizing 
with 5 ~010.4 N perchloric acid. After homogeniza- 
tion the protein precipitate was removed by centri- 
fugation and the supernatant brought to pH 6.0 by 
addition of saturated Ka COa . The precipitate of po- 
tassium perchlorate was removed by centrifugation 
and the supernatant used for the determination of 
PCA. Serum samples were deproteinized by addition 
of perchloric acid and the samples treated similarly 
to the tissue extracts. Isolation of PCA was carried 
out from one ml aliquots of urine and cerebrospinal 
fluid (CSF) and from protein free solutions corre- 
sponding to either 1 g tissue or 1 ml serum. Glutamine 
and glutamate were removed by passing the samples 
through a column of AG50WX8 cation exchange resin 
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(100-200 mesh; 0.7 X 10.0 cm; H form). The effluent 
was further purified sequentially by adsorption of PCA 
on AClX4 (100-200 mesh; 0.7 X 15 cm) and DEAE 
Sephadex A25 (0.7 X 5 cm columns in the chloride 
forms, and carrying out the elution with 0.01 N HCl. 
The final effluent was evaporated to dryness by flash 
evaporation and PCA was converted to a derivative 
with a high electron capture response by reaction with 
a new reagent - 20% pentafluoropropanol in pentaflu- 
oropropionic anhydride [9]. In this reaction pentaflu- 
oropropionic anhydride catalyzes the esterification of 
the carboxyl group of PCA with pentafluoropropanol. 
The recovery of PCA through the procedure was 75%. 
Recovery was determined by adding [14C]L-PCA to 
parallel samples (400,000 cpm; specific activity = 200 
mCi/pmole), and counting the radioactivity in the final 
effluent. Quantitation of PCA in the samples was achiev- 
ed by use of an internal standard curve constructed 
from the peak heights of parallel samples containing 
5-20 I-18 added PCA. To determine the optical config- 
uration of the PCA present in urine and CSF, the sam- 
ples were purified by ion exchange chromatography 
and the isolated PCA determined as described above. 
Aliquots were removed prior to derivatization and con- 
verted to glutamate by acid hydrolysis (2 N HCI, lOO”C, 
4 hr). Following hydrolysis the acid was removed by 
evaporation under reduced pressure and the residue 
dissolved in acetate buffer (0.3 ml; 0.05 M, pH 5.0). 
L-Glutamic acid decarboxylase (0.2 ml; 1 unit) was 
added and the samples were incubated at 37°C for 3 
hr. Samples containing L-glutamate, D-glutamate and 
DL glutamate were run in parallel. y-Amino butyric 
acid which is formed by the action of this enzyme on 
L-glutamate can be derivatized with pentafluoropro- 
panol in pentafluoropropionic anhydride and the de- 
rivative separated by gas chromatography from the de- 
rivatives of glutamate and PCA. 
3. Results 
Both CSF and urine yielded a peak with a retention 
time identical to authentic PCA on eight different col- 
umns coated with liquid phases of varying degrees of 
polarity [3% OV-1,3% OV-17,3% XE-60, 3% OV-225, 
2% XF-1105/3% OV-17 (3/l), 3% ECNSS-M, 10% 
GE-SE-54, and 3% JXR (fig. l)]. The identity of the 
peak was further confirmed by its conversion to ghrta- 
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Fig. 1. Chromatograms of a CSF specimen demonstrating a 
peak with the exact retention time of authentic PCA. 3% JXR, 
12O”C, Na = 40 ml/min; 3% OV-1,12O”C, Na-30 ml/min. 
mate following acid hydrolysis (2 N HCI, lOO”C, 4 hr). 
Glutamate can be derivatized under the same conditions 
as PCA and determined quantitatively. The derivatives 
of these two compounds can be resolved on a number 
of gas chromatographic columns (fig. 2). Acid hydrol- 
ysis of urine and CSF samples prior to derivatization 
resulted in disappearance of the PCA peak and appear- 
ance of a glutamate peak (fig. 2). Additional proof of 
identity was obtained by enzymatic conversion of the 
L-glutamate formed from PCA to y-aminobutyric acid 
(GABA) by the action of L-glutamic acid decarboxylase 
(see below). 
Significant amounts of PCA can be demonstrated in 
both urine and CSF, the mean levels being, respectively, 
0.19 and 0.06 pmoles/ml (table 1). Two human serum 
samples had PCA levels of 0.01 and 0.03 pmoles/ml, 
values which are lower than those found in either urine 
or CSF. Significant quantities of PCA were also found 
in a number of tissues of several species studied. In one 
series of experiments the following values were found 
in organs of the guinea pig: kidney 0.15 pmoles/g, brain 
0.13 pmoles/g, lungs 0.08 pmoles/g, spleen 0.04 pmoles/ 
g, liver 0.03 pmoles/g and heart 0.003 pmoles/g. Simi- 
lar values were found in organs of the rabbit and rat. 
It is well established that nonenzymic cyclization of 
glutamine is substantial even at 37’C. Glutamate, gluta- 
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Fig. 2. Identity of urinary PCA. Chromatographic onditions: 10% GE SE-54, 158°C N2 -60 ml/min. A) Separation of pentaflu- 
oropropionate derivatives of PCA and glutamate. B) Authentic PCA carried through procedure and derivatized. C) Authentic PCA 
hydrolyzed with 2 N HCl for 4 hr at 100°C before derivative formation. D) Urine sample carried through procedure. E) Aliquot 
of sample D hydrolyzed with 2 N NC1 for 4 hr at 100°C prior to derivative formation. 
Table 1 
Levels of pyrrolidone carboxylic acid in urine and cerebro- 
spinal fluid. 
Sample No. of Mean f S.D. Range 
specimens &moles per ml) @moles per ml) 
Cerebrospinal 
fluid 25 0.06 f; 0.02 0.03-O. 11 
Urine 31 0.19 * 0.11 0.04-0.58 
thione and T-glutarnyl amino acids are much more re- 
sistant to cyclization than glutamine. The possibility 
that the levels of PCA found in body fluids were de- 
rived from the nonenzymic cyclization of glutamine 
at some stage of the determination was ruled out by 
processing solutions of glutamine in concentrations 
equivalent to those in serum and CSF. Only a trace of 
material with the retention time of PCA was observed 
(< 0.001 pmoles/ml). We therefore conclude that PCA 
is a normal constituent of body fluids and that it is 
probably derived from normal intermediary metabolic 
processes. 
The reported presence of D-PCA in urine and the 
finding that D-glutamate is converted to D-PCA in viva 
and excreted in the urine [lo] led us to determine the 
optical configuration of the PCA present in urine and 
CSF as described above. The results of one such experi- 
ment are presented in table 2. As can be seen all the 
PCA present in CSF can be converted after acid hy- 
drolysis and incubation with the enzyme to GABA, 
and must therefore be of the L-configuration. The 
same result was obtained with four other cerebro- 
spinal fluids. In contrast only about 44% of the PCA 
in urine was on the L-configuration (table 1). In five 
other urines the amount of L-PCA was found to vary 
between 30 and 40%. Thus although D-PCA seems to 
prevail in the urine, significant amounts of the L-iso- 
mer can also be detected. 
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Table 2 
Determination of optical configuration of pyrrolidone carboxylic acid in urine and cerebrospinal fluid. 
July 1973 
Source PCA 
@moles per ml) 
D-glutamate* 
(umoles per ml) 
y-Aminobutyrate* 
&moles per ml) 
Urine 
Cerebrospinal 
fluid 
0.57 0.30 0.24 
0.07 <O.OOl 0.065 
* Values were obtained after acid hydrolysis and incubation with L-glutamic acid decarboxylase. For details 
see the text. 
4. Discussion Acknowledgements 
These studies provide evidence that PCA is a natu- 
ral constituent of body fluids and tissues and that the 
levels found cannot be derived from the non-enzyma- 
tic cyclization of glutamine. It may be thus assumed 
that PCA is derived from normal intermediary meta- 
bolic processes, most probably from the operation of 
the y-glutamyl cycle, the only known pathway in 
which large amounts of L-PCA can be formed [6]. The 
cycle postulates that the reabsorption of amino acids 
in the kidney is linked to the synthesis and degradation 
of glutathione and thus to the renal synthesis of ATP. 
This idea became attractive [ 1 l] when it was discover- 
ed that y-glutamyl transpeptidase, the enzyme that 
transfers the y-glutamyl moiety of glutathione to 
amino acids [ 121 is heavily concentrated in the brush 
border of the proximal convoluted tubules and other 
sites where transport could be anticipated [ 13- 1.51. 
Supporting evidence for the functioning of the y-glu- 
tamyl cycle in amino acid transport has recently been 
obtained in studies of a metabolic disorder termed 
pyroglutamic aciduria discovered in a 20-year-old 
mentally retarded patient who excretes approx. 30 g 
PCA per 24 hr in the urine [7]. Biochemical studies 
of this disorder [ 161 seem to indicate that the patient 
has a block in the enzymatic step of the y-glutamyl 
cycle in which L-PCA is converted in an ATP requiring 
reaction to L-glutamate [ 171. 
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